Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 161

Sort by

Sort Order Select

Journal Articles

Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma

Preetesh Jain, Holly A Hill, Chi Young Ok, Alexander Nesmalov, Vitaly Segodin, Dmitry Tabakov, Nikita Kotlov, Pavel Zemskiy, Eleonora Belykh, Krystle Nomie, Ahmed Fetooh, Rashmi Kanagal-Shamanna, Fatima Z Jelloul, Guilin Tang, Francisco Vega, Nathan Fowler, Christopher R. Flowers, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2023-181319

Published: 2023

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

ASXL1 / TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions (VAF) in CMML

Clifford M Csizmar, Mark Gurney, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle E. Hammond, Terra L Lasho, Christy M Finke, Christopher Dean, Abhishek A Mangaonkar, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4615.

https://doi.org/10.1182/blood-2023-187235

Published: 2023

Journal Articles

Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia

Blood (2023) 142 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2023-178061

Published: 2023

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Journal Articles

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Preetesh Jain, Hun Ju Lee, Jason Westin, Loretta J. Nastoupil, Luis Fayad, Ranjit Nair, Swami P. Iyer, Rashmi Kanagal-Shamanna, Ahmed Fetooh, Holly A Hill, Chi Young Ok, Wendy Chen, Onyeka Oriabure, Lei Feng, Guilin Tang, Francisco Vega, Maria Badillo, Christopher R. Flowers, Michael L. Wang

Blood (2023) 142 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2023-181312

Published: 2023

Journal Articles

Mutant Natural Killer Cell Dysfunction Enables the Immune Escape of Premalignant MDS Cell Clones

Blood (2023) 142 (Supplement 1): 514.

https://doi.org/10.1182/blood-2023-184349

Published: 2023

Journal Articles

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2023-182256

Published: 2023

Journal Articles

Prognostic Relevance of Truncating ASXL1 Mutations and ASXL1 -Integrated Molecular Models in Proliferative CMML

Clifford M Csizmar, Mark Gurney, Terra L Lasho, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle E. Hammond, Christy M Finke, Abhishek A Mangaonkar, Aref Al-Kali, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 3241.

https://doi.org/10.1182/blood-2023-186881

Published: 2023

Journal Articles

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Danielle E. Hammond, Nicholas J. Short, Farhad Ravandi, Marina Y. Konopleva, Gautam Borthakur, Naval Daver, Rashmi Kanagal-Shamanna, Wei Qiao, Xuelin Huang, Heather Schneider, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2023-178115

Published: 2023

Journal Articles

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Samuel Urrutia, Kelly S. Chien, Ziyi Li, Gautam Borthakur, Yesid Alvarado Valero, Tapan M. Kadia, Steven M. Kornblau, Naval Daver, Farhad Ravandi, Prithviraj Bose, Musa Yilmaz, Maro Ohanian, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2023-184690

Published: 2023

Journal Articles

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features

Hussain Alcassab, Koji Sasaki, Danielle E. Hammond, Alex Bataller, David B Beck, Tapan M. Kadia, Guillermo Montalban-Bravo, Kelly S. Chien, L. Jeffrey Medeiros, Hagop Kantarjian, Awdesh Kalia, Manjunath Nimmakayalu, Carlos E. Bueso-Ramos, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna

Blood (2023) 142 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2023-190464

Published: 2023

Journal Articles

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN)

Blood (2023) 142 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2023-188701

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Blood (2023) 142 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2023-189203

Published: 2023

Journal Articles

Comprehensive Characterization of Evolution of Genomic Complexity By Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure

Hui Yang, Guillermo Garcia-Manero, Kelly S. Chien, Koji Sasaki, Sherry Pierce, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna

Blood (2023) 142 (Supplement 1): 4612.

https://doi.org/10.1182/blood-2023-187719

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial

Blood (2023) 142 (Supplement 1): 3036.

https://doi.org/10.1182/blood-2023-181216

Published: 2023

Journal Articles

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Samuel Urrutia, Kelly S. Chien, Danielle E. Hammond, Koji Sasaki, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2023-179979

Published: 2023

Journal Articles

Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer

Oriol Calvete, Rashmi Kanagal-Shamanna, Julia Mestre, Guillermo Montalban-Bravo, Courtney D. DiNardo, Koji Sasaki, Jessica Aranda, Pamela Acha, Blanca Xicoy, Ana Pérez González, Laura Palomo, Maria Julia Montoro, Mireia Margeli, Francesc Sole

Blood (2023) 142 (Supplement 1): 4593.

https://doi.org/10.1182/blood-2023-188887

Published: 2023

Journal Articles

Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2023-187903

Published: 2023

NARROW

Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

ASXL1 / TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions (VAF) in CMML

Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Mutant Natural Killer Cell Dysfunction Enables the Immune Escape of Premalignant MDS Cell Clones

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Prognostic Relevance of Truncating ASXL1 Mutations and ASXL1 -Integrated Molecular Models in Proliferative CMML

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN)

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Comprehensive Characterization of Evolution of Genomic Complexity By Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer

Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only